Get the Stockscreener App
0.099
3.23%
-0.0033
After Hours:
.10
0.001
+1.01%
Quince Therapeutics Inc stock is traded at $0.099, with a volume of 8.57M.
It is down -3.23% in the last 24 hours and up +0.20% over the past month.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
See More
Previous Close:
$0.1023
Open:
$0.1
24h Volume:
8.57M
Relative Volume:
0.14
Market Cap:
$5.51M
Revenue:
-
Net Income/Loss:
$-56.98M
P/E Ratio:
-0.0812
EPS:
-1.2189
Net Cash Flow:
$-38.98M
1W Performance:
+5.21%
1M Performance:
+0.20%
6M Performance:
-93.96%
1Y Performance:
-92.50%
1-Day Range:
$0.093
$0.10
1-Week Range:
$0.0845
$0.1137
52-Week Range:
$0.08
$4.5499
Quince Therapeutics Inc Stock (QNCX) Company Profile
Name
Quince Therapeutics Inc
Sector
Industry
Phone
415-910-5717
Address
611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO
Compare QNCX vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QNCX
Quince Therapeutics Inc
|
0.099 | 5.51M | 0 | -56.98M | -38.98M | -1.2189 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Quince Therapeutics Inc Stock (QNCX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Aug-05-25 | Initiated | Citizens JMP | Mkt Outperform |
| Mar-24-25 | Initiated | Oppenheimer | Outperform |
Quince Therapeutics Inc Stock (QNCX) Latest News
QNCX PE Ratio & Valuation, Is QNCX Overvalued - Intellectia AI
Quince Therapeutics Inc expected to post a loss of 22 cents a shareEarnings Preview - TradingView
Quince Therapeutics settles $16.4M debt with $5.5M payment - MSN
QNCX Stock Price, Quote & Chart | QUINCE THERAPEUTICS INC (NASDAQ:QNCX) - ChartMill
Quince Therapeutics Delays Annual 10-K Filing - TipRanks
Quince Therapeutics (QNCX) delays 2025 10-K after failed Phase 3; seeks 15-day extension - Stock Titan
QNCX Stock News Today | Earnings, Events & Price Alerts - intellectia.ai
Aug Setups: Will Quince Therapeutics Inc benefit from AI trends2026 Earnings & Fast Moving Trade Plans - baoquankhu1.vn
Quince Therapeutics (QNCX) Resolves Debt with European Investmen - GuruFocus
Quince Therapeutics Settles $16.4 Million in Debt - National Today
Curious about the most active stocks on Monday? - ChartMill
Quince Therapeutics settles EIB loan obligations for $5.5 mln - marketscreener.com
Quince Therapeutics Settles EIB Loan Obligations For $5.5 Mln - TradingView
Quince Therapeutics settles $16.4M debt for $5.5M payment By Investing.com - Investing.com India
Stocks Under $0.10: ITRM, AMLM, BFRG, QNCX, ADMQ March Madness Watch - openpr.com
Quince Therapeutics settles approximately $16.4 million of debt - marketscreener.com
Quince Therapeutics Settles $16.4 Million Debt for $5.5 Million, Advances Strategic Restructuring - Minichart
Quince Therapeutics Eliminates EIB Debt, Boosts Flexibility - TipRanks
Quince Therapeutics, Inc. Settles Approximately $16.4 Million of Debt - marketscreener.com
Why did QNCX stock surge 40% in pre-market today? - MSN
Quince Therapeutics settles $16.4M debt for $5.5M payment - Investing.com
Quince Therapeutics Settles EIB Finance Contract With €4.8M Payment, Ending 2020 Facility - TradingView
Quince Therapeutics (QNCX) retires about $16.4M EIB loan with $5.5M payment - Stock Titan
A $5.5M payment erased Quince debt as it explores merger options - Stock Titan
Quince Therapeutics Settles Approximately $16.4 Million of Debt - Business Wire
Highs Report: Can Quince Therapeutics Inc sustain its profitabilityDollar Strength & AI Driven Price Predictions - baoquankhu1.vn
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Quince Therapeutics stock extends rally on strategic review - MSN
Published on: 2026-03-22 07:39:28 - baoquankhu1.vn
Quince Therapeutics receives Nasdaq notices for bid price and market value By Investing.com - Investing.com South Africa
Quince Therapeutics receives Nasdaq notices for bid price and market value - Investing.com UK
Form 8K Quince Therapeutics Inc For: 20 March By Investing.com - Investing.com
Quince Therapeutics Faces Nasdaq Listing Compliance Deficiencies - TipRanks
Quince Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Quince Therapeutics (QNCX) hit with dual Nasdaq listing deficiency notices - Stock Titan
U.S. Earnings Preview: After Market Close March 20 - news.futunn.com
QNCX stock down 9.59% intraday (NASDAQ) March 20 2026: earnings week in focus - Meyka
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Bear Alert: Is now the right time to enter Quince Therapeutics IncWeekly Trade Analysis & Technical Confirmation Trade Alerts - baoquankhu1.vn
QNCX Quince Therapeutics (NASDAQ) $0.099 intraday 18 Mar 2026: earnings Mar 23 could reset outlook - Meyka
Stock Analysis: How cyclical is Quince Therapeutics Incs revenue stream2026 Market Mood & High Accuracy Trade Alerts - baoquankhu1.vn
Quince Therapeutics (QNCX) Expected to Announce Quarterly Earnings on Monday - Defense World
Quince Therapeutics (QNCX) price target decreased by 33.33% to 4.08 - MSN
What sparked Quince Therapeutics (QNCX) stock to rise 53% after hours - MSN
Can Quince Therapeutics Inc. stock rebound after recent weaknessJuly 2025 Selloffs & Entry Point Confirmation Signals - Naître et grandir
Aug PreEarnings: Is now the right time to enter Quince Therapeutics IncTrend Reversal & Community Trade Idea Sharing Platform - baoquankhu1.vn
Group One Trading LLC holds 5.94M shares in Quince (QNCX) filing - Stock Titan
Quince Therapeutics, Inc. (NASDAQ:QNCX) Given Average Recommendation of “Reduce” by Analysts - Defense World
Trading Recap: Is Quince Therapeutics Inc stock overvalued or fairly priced2025 Technical Overview & Verified Short-Term Plans - baoquankhu1.vn
QNCX SEC FilingsQuince 10-K, 10-Q, 8-K Forms - Stock Titan
QNCX Should I Buy - Intellectia AI
Quince Therapeutics Inc Stock (QNCX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Quince Therapeutics Inc Stock (QNCX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Benatti Luca | Director |
Dec 26 '25 |
Sale |
3.47 |
50,000 |
173,500 |
39,179 |
| Hannah Brendan | CBO, COO & CCO |
Dec 05 '25 |
Option Exercise |
0.91 |
27,551 |
25,012 |
361,827 |
0.49%
1.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):